A range, not a price
The Terms state that the patient care fee ranges between two figures, is paid monthly, and includes a medication credit. Nothing states what determines where in that range a given patient falls: not the dose, not the drug, not the plan.
The top of the range is three times the bottom. A recurring charge published as a three-fold range is a recurring charge a reader cannot budget for.
We have recorded the floor of the published range as the membership amount, because the seller publishes no single figure, and put the whole range in the qualifier so the number is never read alone.
A credit larger than the fee that contains it
At the bottom of the published range, the stated medication credit is larger than the fee. The Terms do not explain how a monthly charge can include a credit worth more than itself.
There are readings that would make it coherent — the credit might only apply at higher tiers, or it might be a notional value rather than money — and the document supplies none of them.
This is recorded exactly as published. It is not a claim that the seller is wrong; it is a claim that the only document publishing its prices does not add up as written.
In-clinic prices, and a host that cannot be size-checked
The same clause prices compounded semaglutide and tirzepatide with a dose ceiling on each, and says the medication is compounded and administered directly from the physician to the patient at the clinic. These are in-clinic figures, not shipped ones.
The Terms carry a copyright line naming the operating limited liability company, dated two years before this reading. That is the only place a company name appears.
A nonsense path on this host returns a not-found status with nearly twenty-four thousand characters of visible text. Anything judged by response size on this domain would confirm an address that does not exist; only the status code separates them.
MultiMedRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/mostarts at, for dosages up to 1.25 mg, and the clause states the medication is "compounded and administered directly from the physician to the patient at the clinic" - an in-clinic figure, not a shipped one. It is published only in the Terms and Conditions | September 2026source |
| Tirzepatide (compounded) | $139/mothe tirzepatide half of the same clause, for dosages up to 10 mg, also in-clinic and also published only in the Terms | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See MultiMedRx's current price →Good fit if
- Readers willing to read a terms document to find out what a seller charges.
- Buyers attending a clinic in person who want an in-clinic dispensing figure with a dose ceiling.
- People who want a recurring fee acknowledged in writing rather than discovered at checkout.
Look elsewhere if
- Anyone who needs to know what they will actually pay each month; the fee is a three-fold range.
- Buyers who want a price on a pricing page.
- Readers who need the medication shipped rather than dispensed at a clinic.
- People who need the pharmacy named or a service area published.
How this review was verified
- Read the Terms and Conditions on 6 September 2026, with a nonsense-path control on the host in the same run that returned a not-found status carrying nearly twenty-four thousand characters of text, so nothing on this host was judged by response size.
- Quoted the patient care fee clause from the Terms rather than paraphrasing it, and recorded the published floor with the whole range in the qualifier.
- Compared the stated credit against the floor of the fee range rather than against its midpoint, which is where the inconsistency appears.
- Found the operating company in the copyright line of the Terms; an earlier research pass on this seller reported that no entity was published at all.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.